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 Abstract 
Objective: To clinically, genetically and radiologically characterize a large cohort of SPG7 
patients 
Methods: We have used next generation sequencing panels for ataxias and hereditary spastic 
paraparesis (HSP) to screen patients attending dedicated ataxia and HSP clinics, and 
subsequently targeted typical phenotypes for direct genetic testing for variations in SPG7. 
Most patients also underwent MR imaging.  
Results: We identified 40 cases with bi-allelic SPG7 mutations, including six novel mutations, 
including a large multi-exon deletion, representing one of the largest cohorts so far described. 
We identified a characteristic phenotype comprising cerebellar ataxia with significant 
cerebellar dysarthria, mild lower limb spasticity and a waddling gait, predominantly from a 
cohort of idiopathic ataxia. We report a novel brain MRI finding of dentate nucleus hyper-
intensity on T2 sequences. . We confirm that the c.1529C>T allele is frequently present in 
patients with long-standing British ancestry. Based on the findings of the present study and 
existing literature we confirm that patients with homozygous mutations involving the M1 
peptidase domain of SPG7 have a younger age of onset compared to individuals with 
mutations elsewhere in the gene (14 years difference, p<0.034), whilst c.1529C>T compound 
heterozygous mutations are associated with a younger age of onset compared to homozygous 
cases (5.4 years difference, p<0.022).  
 
Conclusions: Mutant SPG7 is a common cause of ataxia.  In patients with British ancestry 
c.1529C>T allele represents the most frequent mutation. SPG7 mutations can be clinically 
predicted by the characteristic hybrid spastic-ataxic phenotype described above, along with 
T2 hyperintensity of the dentate nucleus on MRI.   
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Introduction 
Hereditary spastic paraparesis (HSP) and hereditary cerebellar ataxias (HCA) are 
heterogeneous groups of progressive neurodegenerative conditions with significant overlap 
1, 
2
.  HSP can be complicated due to development of cerebellar ataxia, neuropathy, optic atrophy 
and muscle weakness etc. as can HCA 
3
. Moreover the group of ataxias defined as idiopathic 
cerebellar ataxias (ICA) is often sporadic, relatively late onset with apparently variable symptoms 
and with no cause identified after extensive metabolic, autoimmune and genetic work-up, can pose 
a diagnostic challenge. The extensive genetic heterogeneity in HSP with 76 different HSP 
genetic loci, and more than 36 loci associated with autosomal dominant cerebellar ataxias and 
a similar number of autosomal recessive genes 
4-6
 together with the overlapping features of 
HCA and complicated HSP often cause difficulties in classifying and planning genetic testing. 
Next generation sequencing (NGS) is now available for both HSP and HCA patients. However, 
such panel tests currently remain expensive with a considerable burden to the National 
health service (NHS) in the UK. Therefore detailed characterisation of the phenotype of 
currently incurable genetic ataxias and HSP is important in the discovery of underlying 
molecular factors in addition to help understand the natural history of the disorders to 
explore potential bio-markers. We highlight the importance of genotype-phenotype 
correlation beyond the traditional non-specific clinical boundaries of HSP and HCA.  We 
describe our experience in identifying and characterising a large cohort patients with 
mutations in SPG7 gene, implicated in HSP, HCA and ICA
7
, and a review of all published SPG7 
mutations.  
 
 
 
 
Methods 
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Patient Cohorts  
Within the Sheffield Academic Directorate of Neuroscience we have two large cohorts of 
patients with cerebellar ataxia (n=1700) and hereditary spastic paraparesis (HSP) (n=336). 
The Sheffield Ataxia Centre cares for patients with various types of ataxias. The patients are 
under regular review with the aim of identifying the cause of their ataxia as well as to provide 
care and support. All cases are assessed clinically and undergo investigations as clinically 
indicated including MR brain imaging. The severity of ataxia is assessed using the SARA score 
8
 and the severity of spasticity using Spastic Paraparesis Rating Scale (SPRS). The majority of 
patients described in this paper were seen at the Sheffield Ataxia Centre, with the remainder 
being seen in the Sheffield Neuromuscular and Hereditary Spastic Paraparesis clinics.  
 
Genetic testing  
Patient consent was obtained for genetic testing and reporting of findings. Libraries of 
sheared genomic DNA corresponding to panels of either HCA or HSP genes captured using a 
SureSelect XT custom designed probe set (Agilent, Cheadle, UK) and pair-end sequenced using 
a HiSeq 2500 instrument (Illumina) were initially used. Raw data were analysed using the 
Genome Analysis ToolKit 
9
, (GATK, Broad Institute, Cambridge, MA, USA) according to their 
best practice guidelines 
10, 11
. After initial identification of eleven patients with SPG7 
mutations using the ataxia and HSP gene panels we evaluated the phenotype of these 
individuals to identify a triad of spastic paraparesis (usually mild), cerebellar ataxia (with 
prominent cerebellar dysarthria) and a waddling type gait indicative of proximal muscle 
weakness.   Thereafter, the majority of patients who presented with the traditional label of 
HCA or HSP who had the above triad were analysed by bi-directional Sanger sequencing and 
dosage analysis (multiplex ligation-dependent probe amplification kit P213-B1 and B2, MRC-
Holland) of all 17 exons of the SPG7 gene.  The remainder was identified using either HSP or 
HCA gene panel testing as before.   
  
6
 Chromatographs were analysed using Mutation surveyor v4.0.8 
(http://www.softgenetics.com/ms). Annotation of mutations was carried out in accordance 
with Human Genome Variation society nomenclature (http://www.hgvs.org/mutnomen), 
with nomenclature based on the reference sequence NM_003119.3. Novel variants in the SPG7 
gene were assessed for pathogenicity using Alamut Visual version 2.9.0 (Interactive 
Biosoftware, Rouen, France) and prediction software (Provean, MutPred, SNPS&GO and 
PolyPhen2). Allele frequencies for novel variants in normal control populations were 
obtained from the Genome Aggregation Database (gnomAD) 
12
.  
 
Neuroimaging  
Analysis of the imaging was undertaken for all of the patients (N = 38) that underwent brain 
imaging on the same 3T MR scanner (Ingenia, Philips Medical Systems, Eindhoven, 
Netherlands) with the same T2 weighted sequence and compared with age and sex matched 
controls imaged with this sequence (REC reference 09/H1310/79, IRAS 26259). The axial T2 
weighted parameters were: TR 3000ms, TE 80, echo train length 15, number of averages 1 
and 4mm thick, 512 x 512 matrix. Matching criteria for control subjects were age within 3 
years and sex. Relative signal intensity of the dentate nucleus was compared to normal 
appearing pontine white matter and the red nucleus.  A region of interest (area 20mm
2
) in 
these structures, was placed in the region of the dentate nucleus with the lowest signal (by 
NH). The dentate nucleus signal was then dichotomized by whether the ratio of the signals 
was less than or more than 1 (i.e. hypo or hyperintense compared to normal appearing white 
matter in the pons).  
 
Literature review  
We reviewed clinical and genetic details of all SPG7 cases thus far reported in the literature 
(until 30
th
 September 2017). We searched the following terms in Pubmed, Medline, Web of 
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science  and Embase: SPG7, paraplegin, hereditary spastic paraparesis, hereditary spastic 
paraplegia (mutations), spastic ataxia, ataxia, and selected all the papers reporting SPG7 and/ 
or paraplegin mutations and reviewed the phenotype and genotype data published. We 
excluded publications, which were not in English or where English translation was not 
available, and papers that did not describe clinical features but only detailed basic 
experimental science. All mutations described by us and previously reported are depicted in a 
schematic diagram in relation to functionally important domains (Figure 1). 
 
Statistical analyses 
Statistical analysis was performed using Prism GraphPad
TM
 V7.0b and SPSS (2015) statistical 
software programmes. One-way ANOVA was used for multiple group comparisons and 
independent samples t-test and the Chi square test were used to compare two groups. 
 
Results 
Characterisation of the phenotype 
We identified a total of 40 cases positive for pathogenic mutations in both alleles of the SPG7 
gene (Table 1). Initially 11 cases were found to have pathogenic SPG7 mutations using ataxia 
or HSP next generation sequencing (NGS) gene panels. More specifically, in four patients the 
detection was made using the ataxia panel, which consisted of 42 ataxia genes, and in seven 
patients the detection was made using the HSP panel of 39 genes. In five of the seven HSP 
panel cases the HSP like phenotype was complicated with cerebellar features and only two of 
the seven HSP cases had a pure HSP phenotype. Reviewing the phenotype of these 11 cases, 
we noted that 9 individuals had cerebellar ataxia with prominent slurring of speech, mild 
spasticity and proximal muscle weakness resulting in a waddling gait.  
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Direct genetic screening based on the phenotype 
Following the clinical characterisation of the initial 11 patients, we undertook direct testing 
for mutations in the SPG7 gene in patients who demonstrated the above phenotype of 
cerebellar ataxia, spasticity (often mild) and waddling gait in a cohort of patients attending 
the Sheffield Ataxia Clinic and hereditary spastic paraparesis clinics. We identified a further 
26 cases (24 from the ataxia clinic and 5 from the neuromuscular clinic) with pathogenic 
mutations in the SPG7 gene. The method of genetic testing and basic clinical phenotype are 
detailed in Table 1. All cases were positive for bi-allelic mutations in the SPG7 gene (Table 1).  
 
Clinical characteristics of patients with SPG7 mutations 
The clinical characteristics of the 40 probands are summarized in Table 2. There was no 
history of consanguinity. Eighty-five percent were male. The average age of symptom onset 
was 41.7 years (SD 11, median age 44 years). Female patients developed symptoms on 
average 8 years younger than males (38.5 years vs 46.6)(Table 3). The mean duration of the 
disease at the time of diagnosis was 9 years (SD±4.9, mode 5). Thirty-six out of forty were of 
long standing British ancestry. Four were UK citizens of Indian, Iranian, German and 
Bulgarian descent.  Of these four cases, three were phenotypically similar to the majority of 
the cohort, whilst the female patient from Bulgaria had cerebellar ataxia at presentation with 
very mild spasticity and later developed a waddling gait. 
Ninety eight percent of cases (39/40) presented with gait unsteadiness followed by 
dysarthric speech (29%). Twenty-nine (74%) complained of mild spasticity. Only two 
patients presented with the typical spastic gait characteristic of HSP (5%) and only 7/40 
presented with moderate to severe spasticity related complaints.  Eighty two percent of our 
cohort had mildly increased lower limb tone and more than 93% had brisk reflexes, whilst the 
Babinski sign was positive in 51%. 
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At baseline assessment  36/40 cases (90%) were found to have evidence of cerebellar ataxia 
and 31/40 cases were found to have both mild spasticity and cerebellar ataxia. Despite the 
cerebellar features, only 2/40 cases were non-ambulant at the time of writing the paper, with 
a total symptomatic disease duration of 369 patient years. None of the patients could run and 
78% of the cases were using some type of walking aid. The severity of the ataxia, as assessed 
by the SARA score, was less severe (the average SARA score was 10.58 with a median of 10.0) 
when compared to other inherited ataxias such as SCA 6 (median score 15.0) for the same 
duration of symptoms.  
Sixty four percent (25/40) of cases demonstrated the triad of cerebellar ataxia with 
dysarthria, spasticity and waddling gait at presentation and 9 others developed the full 
clinical picture during subsequent follow-up (totalling 87%). Progressive external 
ophthalmoplegia (PEO) was observed only in one case. In another patient we noted vertical 
gaze palsy. Nystagmus was present in 38% (15/40). Optic atrophy was seen in one patient. 
Waddling gait was seen in 87% of our cases.  
Although four patients were found to have reduced vibration sense and 3 had reduced 
pinprick sensation on clinical examination, none of the 19 patients who underwent 
neurophysiological assessment had evidence of large fibre peripheral neuropathy. The 
neurophysiological assessments did not suggest evidence of myopathy on EMG.  
 
 
Mutation analysis 
Fifteen cases were homozygous for mutations in the SPG7 gene (37%) whilst 25 (63%) cases 
were compound heterozygous. Twelve of the 15 homozygous cases had the common missense 
mutation in exon 11, c.1529C>T, p.(Ala510Val), whilst the other three cases were 
homozygous for the c.233T>A, p.(Leu78*) nonsense mutation.  36/40 cases in our cohort who 
carried the common mutation p.(Ala510Val) in at least one allele were of long standing British 
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ancestry. The three patients homozygous for the p. (Leu78*) nonsense mutation were second-
generation British citizens of Indian, Iranian or Bulgarian descent. The other case,  of German 
descent,  was compound heterozygous for the c.1181T>C, p.(Phe394Ser) and c.1045G>A, 
p.(Gly349Ser) mutations.  
The frequency of the c.1529C>T, p.(Ala510Val) mutation in our cohort was 60% (48 out of 80 
alleles assessed). The second most common mutant allele (6 alleles), c.233T>A, p.(Leu78*) 
was seen in 3 patients in the homozygous state,  whilst c.1045G>A, p.(Gly349Ser) was seen in 
five cases in a compound heterozygous state (5 alleles). p.(Ala510Val) and 
p.Arg485_Glu487del mutations were observed in two thirds of the disease alleles (50/78). In 
addition to the single case with a large deletion, several small insertions, duplications, 
deletions and splice site mutations were detected on 7 alleles, 5 of which have been 
previously described. Most of the pathogenic alleles were missense mutations (60/80) whilst 
20 were nonsense mutations (Table 1).  
 
Novel mutations in SPG7 
We discovered six novel likely pathogenic mutations in the SPG7 gene (Table 1) of which five 
were null mutations, with two frame-shift mutations c.775_781dup p.(Thr261fs) and 
c.2096dup p.(Met699fs), two nonsense mutations c.754G>T, p.(Gly252*) and c.300T>A, 
p.(Tyr100*) and a large deletion encompassing at least exons 4 to 9 (c.377-?_1324+?del) was 
identified using MLPA. The novel missense mutation c.2083C>G, p.(Leu695Val) resulted in 
substitution of the same amino acid as a previously reported pathogenic mutation c.2084T>C, 
p.(Leu695Pro) 
13
. Predictions by PROVEAN (deleterious), PolyPhen2 (Probably Damaging) 
and MutPred (Actionable hypothesis) suggested likely pathogenicity, but this was not 
supported by SNPS&GO (Neutral). This allele is present in the East Asian gnomAD normal 
control population at a frequency of 0.4626%. Interrogation of the exome sequencing data 
repository did not show any of the other novel mutations to be present in healthy controls.   
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MRI Brain imaging  
MRI brain imaging was available in 38 cases. Cerebellar atrophy was noted in 92% (35/38). 
T1 axial sequences indicated cerebellar atrophy (Figure 2A and 2B) and T1 sequences of both 
dentate nuclei (DN) and the red nuclei (RN) were not distinguishable between controls and 
SPG7 cases (Figure 2A and 2C). The same T2 sequence on 3T imaging, as detailed above, was 
available for 21 patients and these were matched with 17  normal controls.  The control group 
had 15 males, 2 females with a mean age of 52.3 years (range 37 to 68). In sixteen control 
subjects the dentate nuclei were hypointense compared to normal appearing white matter 
(Figure 2C), and 1 control subject had dentate nuclei isointense relative to normal appearing 
white matter.  In the patient group there were 18 males and 3 females, mean age 53.8 (range 
38 to 71). Three of the 21 patients had hypointense dentate nuclei compared to normal 
appearing white matter.  The dentate nuclei were iso- or hyper-intense compared with 
normal appearing white matter (T2 imaging) in 18 of the 21 SPG7 positive cases (Figure 2D). 
The increase in DN T2 hyperintensity on MRI in SPG7 cases is significant compared to the 
controls (Chi square test value 25.76, significant at p<0.001)(Figure 2F). Both controls and 
patients showed no difference in the appearance of the red nuclei (RN), which were hypo-
intense compared to normal appearing white matter in the pons (Figure 2E). 
 
 
Genotype – phenotype correlation from current and other studies 
All cases with long standing British ancestry carried at least one allele with the c.1529C>T 
SPG7 mutation,  making it the most frequent mutational site in this cohort.  
After analysing all bi-allelic SPG7 cases reported in the literature we were able to identify 
some associations. We analysed whether mutations in the different functionally important 
domains of SPG7 shown in figure 1 had an impact on the age of onset of symptoms. Patients 
  
12
who had a homozygous mutation in the M1 peptidase domain had an earlier onset of disease 
symptoms by 12 years compared to patients with mutations in a non-functionally assigned 
domain (p<0.022)(Figure 3A).  Having homozygous, compound heterozygous mutations or 
the presence of null alleles did not have an impact on age at disease onset. We also noted that  
patients with the c.1529C>T mutation (which is located in a functionally unassigned domain) 
when in a compound-heterozygote state developed symptoms 8 years earlier compared to 
c.1529C>T homozygous cases  (p<0.019, unpaired t-test)(Figure 3B).  
 
Discussion 
We describe a large cohort of 40  unrelated cases with mutations in the SPG7 gene primarily 
presenting with cerebellar ataxia and less commonly with features of HSP. To our knowledge 
our cohort is the second largest in the world so far reported after a large Dutch cohort of 46 
unrelated families 
14
. We propose the novel observation that the phenotype of cerebellar 
ataxia (with dysarthria), mild lower limb spasticity and a waddling gait is clinically distinct 
and should alert clinicians to direct genetic testing for mutations in the SPG7 gene. Such an 
approach identified 65% of our cohort of patients, whilst next generation sequencing panels 
identified the remainder of this cohort of index cases.  In addition, it is clear that the SPG7-
related phenotype is more likely to present as a cerebellar ataxia, whereas only 23% of our 
cohort was thought to have an hereditary spastic paraparesis phenotype. SPG7 bi-allelic 
mutations have historically been associated with HSP, but over the last 12 years since the 
discovery of pathogenic mutations in this gene, it is now clear that ataxia is the major clinical 
finding 
7, 15, 16
. In another UK based study, SPG7 accounted for 18.6% of 70 patients with 
unexplained ataxia with pyramidal signs (Pfeffer et al 2015). We have found SPG7 to be the 
fourth  commonest cause of any genetic ataxia after Friedreich’s ataxia (FA), spino cerebellar 
ataxia 6 (SCA6) and episodic ataxia 2 (EA2), and the second commonest recessive ataxia in the 
UK after FA based on a large cohort of 1500 patients with various causes of ataxia attending 
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the Sheffield Ataxia Centre
17
. In support for this finding, 90% of our SPG7 cohort 
demonstrated gait ataxia with cerebellar dysarthria (a common feature in 74% of the cases), 
however other cerebellar features were less common (Table 2).  
Only 2 out of 40 patients in our cohort were non-ambulant or wheelchair-dependent. In 
keeping with this observation was the relatively modest median SARA score of 10 indicating 
that ambulatory loss appears to be relatively rare in SPG7 cases 
16
.  This favourable prognostic 
factor will be useful when counselling SPG7 patients and their families.  
A significant proportion of our cases were male (83%), but interestingly female patients 
tended to develop symptoms about five years earlier than male patients. The median age of 
onset of symptoms was 44 years, indicating that SPG7 is a late onset disease. The recessive 
inheritance almost certainly accounts for the lack of a positive family history and therefore 
absence of a family history should not deter from SPG7 testing. Our findings are in keeping 
with a number of previous reports proposing that SPG7 is a late onset disease 
14, 18
. The age of 
onset however did range between 15 to 60 years. Rarely, therefore SPG7 can present with an 
early onset ataxia  
Progressive external ophthalmoplegia (PEO) was only seen in one of our patients but has 
been reported in 11% SPG7 cases worldwide (Supplementary table 1). A previous report by 
Pfeffer et al, 2016 found 9/68 (13%) patients with PEO to be associated with bi-allelic SPG7 
mutations. PEO was also suspected (slow saccades) in one out of five cases in a UK cohort of 
complex HSP 
19
.  Nevertheless PEO associated with mutations in the SPG7 gene was also 
reported to be rare in other cohorts including a French group of patients with spasticity and 
optic neuropathy (2/23) 
20
 and a Dutch HSP cohort (2/46)
14
. A cohort of French Canadian 
patients did not have any families with PEO (none of the 22 individuals from 12 pedigrees) 
16, 
21
 . This variability in the detection of PEO could be related to several factors such as 
ascertainment bias, duration of disease or length of follow up. A longitudinal follow-up study 
on SPG7 patients from the UK reported a median follow-up duration of 23 years from initial 
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presentation before detecting PEO 
7
 as did a Norwegian group (median follow up during 
which PEO recorded was 24 years) 
22
. Taken together, clinicians should be aware that PEO-
like features can develop in SPG7 cases with longer disease duration. 
Optic neuropathy was reported in 9.5% of the worldwide SPG7 cases, compared to our cohort 
where both PEO and optic neuropathy were only seen in one patient. We did not undertake 
optical coherence tomography (OCT), which may in part explain the lower frequency of optic 
neuropathy identified in the present study. In a French cohort of SPG7 patients with spastic 
gait, 44% of the patients had evidence of optic neuropathy based on OCT, whilst 40% of the 
patients with optic neuropathy had normal appearing optic discs on fundoscopy. Two patients 
were found to have optic neuropathy during a subsequent follow-up period of 3-9 years 
20
. 
Therefore a longer follow-up period and the use of OCT may increase the frequency of optic 
neuropathy in SPG7 patients.  
The increased T2 signal from the dentate nucleus in SPG7 cases compared to controls has not 
been previously described. The dentate nucleus is a site of iron accumulation in normal aging 
and this is associated with reduced T2 signal. The high signal in the dentate does not appear 
to be due to a globally reduced brain iron accumulation, with the red nucleus continuing to be 
hypo-intense relative to normal appearing white matter in the patient group as normally 
expected. In support of the MRI findings reported here is the post-mortem brain and 
brainstem analysis from a c.1529C>T homozygous case, that showed neuronal loss in the 
dentate nucleus 
23
. Whilst the exact pathophysiology of the above imaging finding needs 
further investigation, we propose that dentate nucleus hyperintensity on T2 sequences of the 
MRI brain could aid in the diagnosis of SPG7. MRI findings in the combined worldwide cohort 
have not been reported consistently.  We have found that 92% of our cohort had cerebellar 
atrophy on MRI. 
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The waddling gait sign we report here has not been previously highlighted. There are a 
number of reports that describe muscle weakness over and above the mild pyramidal-type 
weakness one might usually expect to see in patients with HSP 
20
. In keeping with our 
observations, myopathic features were noted in the cohort of PEO patients described by 
Pfeffer et al 
18
. Furthermore two thirds of the SPG7 cases from a Dutch cohort were noted to 
have lower limb muscle weakness, although the pattern of weakness could have been 
attributed to upper motor neuron involvement 
14
.  On close scrutiny of the previously 
published papers, one could recognise the presence of myopathic features that can result in a 
waddling gait due to proximal leg muscle weakness. This may also account for the rationale of 
performing muscle biopsies in some cases that have, on occasions, shown evidence of 
mitochondrial dysfunction 
15, 20, 24, 25
.  Disordered mitochondrial maintenance has been 
observed in these patients 
18
. We did not find neurophysiological evidence of large fibre 
peripheral neuropathy or myopathy in our cohort.  
At present more than 242 cases of SPG7 have been described worldwide (supplementary 
table 1). However only 216 of the 242 cases harbour bi-allelic SPG7 mutations, whilst 26 cases 
carry a heterozygous mutation. Analysis of the mutations demonstrates that there is 
considerable genetic heterogeneity, with more than 96 different mutations in the SPG7 gene 
described to date (supplementary table 1). In our cohort we identified six novel mutations. All 
except one resulted in premature truncation of the paraplegin protein and in silico modelling 
has suggested pathogenicity.  The c.1529C>T mutation was present in at least one allele in all 
of our patients with long standing British ancestry, strongly supporting a previous report of 
its association with patients with British heritage 
15
.  The four cases who did not harbour the 
c.1529C>T mutation, were first generation migrants from Europe or Asia. We have also 
observed that when all published mutations are analysed, c.1529C>T is the commonest 
mutation making it the ‘hot spot’ in the SPG7 gene. The common allele (c.1529C>T) frequency 
in our cohort was 60% when compared to 38% of all published SPG7 mutant alleles 
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(164/432). The c.1454_1462del mutation is the second most common mutation worldwide, 
with an allele frequency of 9% (38/432) whilst the third most common allele was c.233T>A, 
p.(Leu78*) at 7% (31/432 alleles) (supplementary table 1).  
In addition to the cohort of 40 cases of bi-allelic SPG7 mutations described here, we have 
identified eight cases who were heterozygous for the c.1529C>T common allele with no other 
SPG7 variation in the second allele, even after MLPA gene dosage assessment (data not 
included).  In the majority of these cases the clinical phenotype was very suggestive of SPG7 
as described above. An autosomal dominant pattern of inheritance has been previously 
suggested in association with mutations in the SPG7 gene in individuals carrying the 
c.1529C>T common allele.  However, the allele has a frequency of 3-4% in the British 
population 
25, 26
, which poses significant doubt about its pathogenicity when found in the 
heterozygous state.  
We conclude that SPG7 is a common cause of sporadic ataxia. We recommend direct genetic 
testing for SPG7 mutations when cerebellar ataxia with dysarthria is associated with mild 
lower limb spasticity and a waddling gait. If the patient is of long standing British ancestry, 
directly testing for the c.1529C>T mutation is highly likely to be diagnostic. MR imaging 
demonstrating cerebellar atrophy with relative T2 hyperintensity of the dentate nuclei is also 
strongly supportive of SPG7. Taken together, we report the importance of detailed genotype, 
phenotype and radiological characterisation to understand the natural history of late onset 
genetic ataxias and hereditary spastic parapareses.  In addition, this approach is likely to 
improve diagnostic efficiency and reduce the expense  of NGS based genetic panel tests in 
patients with the characteristic triad of clinical features and the imaging changes described in 
this report.  
 
 
 
  
17
Figure Legends 
Figure 1. Schematic diagram of the SPG7 protein with important functional domains and 
positioning of mutations in the Sheffield cohort and all the published pathogenic mutations in 
the SPG7 gene. Mutations described in our cohort of patients are annotated above the SPG7 
protein structure, whilst previously published mutations are labelled below. Allelic variation 
frequency is noted within parenthesis. New mutations detected in our cohort are highlighted 
in red font. Variations denoted in blue are matching c.DNA sequence of the reported 
mutations. Some large exon deletions reported are in indicated in the text box. Parentheses 
from mutations removed to create space. TM1 and TM2: Trans-membrane domain 1 and 2; 
FtsH: Filamentation temperature sensitive mutant in E.coli domain; Coil1 and Coil2: Coiled 
domain; AAA: ATPases associated with diverse cellular activities. Reference 
sequence:NM_003119.3. 
 
Figure 2. Magnetic resonance imaging (MRI) of the brain in SPG7 spastic ataxia cases shows 
T2 hyperintensity of the dentate nucleus. A) T1 axial image across the dentate nucleus (DN) of 
a control case. B) T1 axial section through the DN in a patient with c.1529C>T homozygous 
mutation. C) T2 weighted axial image of the same control and D) T2 axial section through DN 
in the same patient with c.1529C>T homozygous mutation which demonstrates hyper-intense 
DN (solid white arrow) compared to the normal appearing white matter. E) T2 weighted axial 
image of the same patient, which demonstrates the red nucleus (RN). The RN appears hypo-
intense compared to normal appearing white matter in all SPG7 and control cases (solid black 
arrow with white boarder). F) The observation of hyper-intense T2 signal of the DN was 
significantly more frequent in the SPG7 patients compared to the control cases (p<0.001, Chi 
square test value 25.7649). 
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Figure 3. Genotype phenotype correlation in SPG7 mutations and age of onset of symptoms. 
(A) Association of the position (by the functionally important regions) of the mutation and the 
age of onset in homozygous SPG7 cases.  N terminal = up to first 140aa; FstH = 141-250aa; 
AAA ATpase = 306-481aa; M1 Peptidase = 544-746aa; The rest = mutations in any other 
area/s which is/are not described as above. We selected homozygous cases due to the 
uniformity they create by harbouring two similarly mutated alleles, to compare the effect of 
the mutation within functionally important domains of the SPG7 protein on the age of onset. 
One-way ANOVA with multiple comparisons and post hoc Tukey test showed a significantly 
(p=0.034) younger age of onset (14.63 years, SE 5.25, 95% CI 0.82 - 28.4) for those with 
homozygous mutations in the M1 peptidase domain compared to a mutational position in a 
functionally undefined domain (‘The rest”). (B) The c.1529C>T common mutation when in the 
homozygous state is associated with a significantly later age of onset that when in the 
compound  heterozygous state. c.1529C>T patients provide a degree of mutational 
homogeneity in that at least one allele is constant allowing comparison between homozygous 
and compound heterozygous states. Compound heterozygotes developed symptoms on 
average 5.4 years earlier than the c.1529C>T homozygotes (p=0.022, independent samples t-
test for equality of means with equal variances assumed). 
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Table 1: SPG7 gene mutations and clinical features at presentation 
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Clinical diagnosis prior to genetic testing 
(HSP- hereditary spastic paraparesis, CA- 
cerebellar ataxia) 
 
 
Mutation in cDNA
1 
 
 
Predicted Protein change  
  
C
e
r
e
b
e
l
l
a
r
 
 
S
p
a
s
t
i
c
i
t
y
 
P
r
o
x
i
m
a
l
 
w
e
a
k
n
e
s
s
 
D
y
s
a
r
t
h
r
i
a
 
P
E
O
 
O
p
t
i
c
 
a
t
r
o
p
h
y
 
B
l
a
d
d
e
r
 
D
i
s
t
u
r
b
a
n
c
e
 
         Allele 1
 
 Allele 2 Allele 1  Allele 2        
1 M 45 5 Direct CA with spasticity, waddling gait  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + + ? - - + 
2 M 44 5 Ataxia CA with spasticity, waddling gait  c.1529C>T c.1937-2A>G p.(Ala510Val) p.? + + + + - - + 
3 M 30 10 HSP CA with spasticity, waddling gait  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + ++ + - - - + 
4 M 40 6 Direct CA with spasticity, waddling gait  c.1529C>T c.1454_1462del p.(Ala510Val) p.(Arg485_Glu487 del) + ++ + + - - + 
5 M 50 6 HSP CA with spasticity, waddling gait  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + + + - - - 
6 M 56 5 HSP HSP-  complicated c.1529C>T c.1045G>A p.(Ala510Val) p.(Gly349Ser) + +++  - + - - - 
7 M 15 14 Direct CA with spasticity  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + +++ + + - - - 
8 M 60 5 HSP HSP-  pure c.1529C>T c.1045G>A p.(Ala510Val) p.(Gly349Ser) - +++ - - - - + 
9 F 24 9 Ataxia CA with spasticity  c.1529C>T c.1904C>T p.(Ala510Val) p.(Ser635Leu) ? + - + - - - 
10 M 51 5 Direct CA with spasticity  c.1529C>T c.1454_1462del p.(Ala510Val) p.(Arg485_Glu487del) + + - + - - - 
11 M 35 6 Direct CA with spasticity, waddling gait  c.1529C>T c.1192C>T p.(Ala510Val) p.(Arg398*) + + + - - - + 
12 M 30 6 Direct CA with spasticity  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + - + - - + 
13 M 44 6 Direct CA with spasticity, waddling gait  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + + ? - - ? 
14 M 37 18 Direct CA with spasticity, waddling gait  c.233T>A c.233T>A p.(Leu78*) p.(Leu78*) + + + + - + + 
15 M 37 8 Direct CA with spasticity  c.1529C>T c.861+2dupT p.(Ala510Val) p.(Asn288*) + + -  + - - - 
16 M 46 5 Direct CA with spasticity, waddling gait  c.1529C>T c.1715C>T p.(Ala510Val) p.(Ala572Val) + + + + - - - 
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17 M 57 4 Direct HSP - complicated c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + -  + - - ? 
18 M 29 10 Direct CA with spasticity, waddling gait  c.1529C>T c.1192C>T p.(Ala510Val) p.(Arg398*) + ++ + + - - + 
19 M 48 6 Direct HSP -  complicated c.1529C>T c.1045G>A p.(Ala510Val) p.(Gly349Ser) + + -  + - - - 
20 M 44 10 Direct HSP -  complicated c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + +  - + - - - 
21 F 35 10 Direct CA with spasticity, waddling gait  c.1529C>T c.1672 A>T p.(Ala510Val) p.(Lys558*) + + + - - - + 
22 M 55 12 HSP HSP -  pure c.1529C>T c.775_781dup p.(Ala510Val) p.(Thr261fs) - +++   - - - + 
23 M 50 7 Direct CA with spasticity, waddling gait  c.1529C>T c.1053dupC p.(Ala510Val) p.(Gly352fs) + + + + - - - 
24 F 48 20 Direct CA with spasticity, waddling gait  c.1529C>T c.861+2dupT p.(Ala510Val) p.(Asn288*) + + + + - - + 
25 M 31 10 Direct CA with spasticity, waddling gait  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + + + - - ? 
26 M 34 10 Direct CA with spasticity, waddling gait  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) ? N + + - - - 
27 M 48 7 Direct CA with spasticity, waddling gait  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + + + - - + 
28 M 36 5 Ataxia CA  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + N + + - - + 
29 F 15 20 Direct CA with spasticity, waddling gait  c.1529C>T c.1904C>T p.(Ala510Val) p.(Ser635Leu) + N + + - - + 
30 F 45 8 Ataxia CA  c.233T>A c.233T>A p.(Leu78*) p.(Leu78*) + + + + - - + 
31 M 30 20 HSP HSP - complicated c.1529C>T c.1045G>A p.(Ala510Val) p.(Gly349Ser) + + + + - - + 
32 M 46 6 HSP HSP - complicated c.1181T>C c.1045G>A p.(Phe394Ser) p.(Gly349Ser) + + + + - - + 
33 M 55 7 Direct CA with spasticity, waddling gait  c.1529C>T c.2096dup p.(Ala510Val) p.(Met699fs) + + + - - - - 
34 M 42 5 Direct CA with spasticity  c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + +  ? + - - ? 
35 M 46 3 Direct CA with spasticity, waddling gait  c.1529C>T c.377-?_1324+? 
del (exon 4-9) 
p.(Ala510Val) p.? + + + + + - ? 
36 F 58 20 Ataxia CA c.1529C>T c.2083C>G p.(Ala510Val) p.(Leu695Val)  + N - + - - - 
37 M 40 12 Direct CA with spasticity, waddling gait  c.1529C>T c.754G>T   p.(Ala510Val) p.(Gly252*) + + + + - - + 
38 M 43 16 Direct CA with spasticity and waddling gait c.233T>A c.233T>A p.(Leu78*) p.(Leu78*) + + + - - - + 
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39 M 44 10 HSP HSP - complicated- ataxia waddling c.1529C>T c.1454_1462del p.(Ala510Val) p.(Arg485_Glu487del) + ++ ++ - - - - 
40 F 45 12 Ataxia CA and mild spasticity but no waddling c.1529C>T c.300 T>A p.(Ala510Val) p.(Tyr100*) ++ + - ++ - - + 
Reference sequence: NM_003119.3. (Key: +: mild (or feature present), ; ++: moderate severity,  +++: severe, ?: unknown; N: normal; -: reduced (or feature not present). In Bold are new mutations detected. 
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Table 2. Phenotypic description of the patients with SPG7 mutation 
Features Index cases (%) 
Male: female ratio 33 : 7 
Mean age at onset  in years (SD) 41.7 (±11 ) 
Mean age of onset for Males in years (SD) 46.6 (±10) 
Mean age of onset for Females in years (SD) 38.5 (±15) 
Mean disease duration at examination in years (range) 9.2 (3-20years) 
 
Symptoms at presentation  
Impaired balance 39/40   (98%) 
Slurred speech 30/40    (75%) 
Stiffness 30/40   (75%) 
Leg weakness 8/40       (20%) 
 
Other symptoms at 
presentation 
Cognitive disturbance 5/40      (13%) 
Deafness 1/40      (2.5%) 
Bladder disturbance 20/40    (50%) 
Muscle weakness 19/40    (48%) 
 
 
Cranial nerve examination  
Nystagmus  15/40   (38%) 
Vertical gaze palsy 1/40       (2.5%) 
Horizontal gaze palsy and limited vertical gaze 1/40       (2.5%) 
Optic atrophy 1/40       (2.5%) 
 
Cerebellar signs 36/40    (90%) 
 Dysdiadochokinesia 16/33   (48%) 
Finger nose test impaired 13/33    (39%) 
Heel shin test impaired 22/33    (67%) 
Cerebellar dysarthria 30/40    (75%) 
Pure spastic gait 2/40       (5%) 
   
 Upper limbs Normal  25/40    (63%) 
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Muscle tone Increased tone 5/32       (16%) 
Lower limbs Normal or reduced 3/39       (8%) 
Increased tone 37/40    (93%) 
 
 
Power 
Upper limbs Normal 31/34    (91%) 
Reduced 3/34       (9%) 
Lower limbs Normal 31/40    (78%) 
Reduced 20/40    (50%) 
 
 
Sensation 
Vibration Normal 29/40    (73%) 
Reduced 4/33       (12%) 
Pin-prick Normal 30/33     (91%) 
Reduced 3/33        (9%) 
Joint position sense Normal 33/33   (100%) 
Reduced  0/33       (0%) 
 
 
Tendon reflexes 
Upper & lower limbs 
 
Normal or reduced (1) 3/40       (8%) 
Brisk 37/40     (93%) 
Babinski Positive 19/37     (51%) 
Negative 18/37     (49%) 
 
 
Gait 
Spastic ataxia 31/40     (78%) 
Pure cerebellar gait 5/40       (13%) 
Spastic waddling gait 4/40      (10%) 
 
MRI Brain Cerebellar atrophy 35/38    (92%) 
 
 
 
 
Supplementary table 1 (uploaded separately) 
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